April 25, 2023
- April 25, 2023 - Notice of Early Expiration of RFA-HG-21-041 "New Investigators to Promote Workforce Diversity in Genomics, Bioinformatics, or Bioengineering and Biomedical Imaging Research (R01 Clinical Trial Optional)". See Notice NOT-HG-23-039.
- June 9, 2022 - Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional). See NOFO PAR-22-181.
National Human Genome Research Institute (NHGRI)
The purpose of this Notice is to inform potential applicants of the National Human Genome Research Institute’s (NHGRI) participation, starting with the September 06, 2023 receipt date, in the funding opportunity announcement (FOA) PAR-22-181, Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional).”
The following sections of PAR-22-181 have been modified to reflect the NHGRI’s and All of Us’ participation in this Notice of Funding Opportunity (NOFO):
Part 1. Overview Information
Components of Participating Organizations
Currently Reads:
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
National Institute of Nursing Research (NINR)
National Center of Complementary and Intergrative Health (NCCIH)
National Eye Institute (NEI)
National Institute on Alchohol Abuse and Alcoholism (NIAAA)
Modified to Read (changes shown in bold italics):
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
National Institute of Nursing Research (NINR)
National Center of Complementary and Intergrative Health (NCCIH)
National Eye Institute (NEI)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Human Genome Research Institute (NHGRI)
Assistance Listing Number(s)
Currently Reads:
93.853, 93.279, 93.242, 93.361, 93.213, 93.273, 93.867,
Modified to Read (changes shown in bold italics):
93.853, 93.279, 93.242, 93.361, 93.867, 93.286, 93.172
Section I. Funding Opportunity Description
Specific Areas of Research Interest:
Currently Reads:
NIDA
NIDA will support applications that address or seek fundamental knowledge related to addiction sciences, including, but not limited to: cellular and molecular neuroscience, neuroimaging, genetics, medication and treatment development, development of new and improved strategies to prevent substance use and its consequences, neuroimmune signaling, neuropathology in brain systems, cognitive processes, population neuroscience, HIV and drugs of abuse (including basic discovery science research as well as applied research on delivery of HIV and substance use prevention and treatment services to persons who use drugs), medication development, epidemiology, identifying the biological, environmental, behavioral, and social causes and consequences of substance use and addiction across the lifespan, and implementation science, including secondary data analysis. In all these and related areas of addiction sciences research, NIDA encourages an emphasis on understanding and addressing health disparities which are experienced by vulnerable populations. Only applications that fall within the scientific mission of NIDA will be considered for funding (https://nida.nih.gov/about-nida/strategic-plan/directors-message).
NIMH
The mission of the National Institute of Mental Health (NIMH) is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery, and cure. NIMH supports research on topics that include basic neuroscience and behavioral science, and translational application of brain and behavior relationships in healthy and diseased states. Mental disorders may be defined according to existing diagnostic criteria or along dimensions of neurobehavioral functioning according to the NIMH Research Domain Criteria (RDoC) framework. If existing diagnostic criteria are to be used, investigators should include plans for addressing heterogeneity within the diagnostic category or categories. Applications considered for funding by the NIMH must fall within the areas of priority detailed in the NIMH Strategic Plan and the NIMH Strategic Research Priorities. It is recommended that investigators contact NIMH Scientific/Research staff well in advance of submitting applications to discuss the match to NIMH priorities. NIMH supports mechanistic clinical trials that focus on biomarker studies that may provide information about physiological function, target engagement of therapeutics, and/or the impact of therapeutic responses. These types of studies do not have as a primary aim to establish the efficacy or effectiveness of the intervention.
NIMH considers two major categories of mechanistic trials (though there may be others):
- Mechanistic clinical trials using an intervention of known efficacy. These clinical trials utilize an efficacious intervention to investigate the pathophysiology, and/or psychopathology of mental disorders or the mechanisms of therapeutic responses; and to advance biomarkers of basic neurobiological processes. In such studies: (1) the primary aims do not involve establishing efficacy/effectiveness, and (2) the intervention chosen has already been demonstrated to have efficacy.
- Mechanistic clinical trials utilizing an experimental manipulation: These studies utilize experimental manipulation and are primarily focused on understanding brain function in healthy individuals or those with mental disorders by measuring responses to the experimental manipulation. They are not intended to inform on the improvement of the health status of the individual or a group of individuals either by better understanding the mechanism of action of an intervention or a measurable improvement in health.
See the “Consolidated Notice on NIMH Clinical Trials Policies,”NOT-MH-20-105, for a summary of NIMH’s polices on support for mechanistic clinical trials.
NINDS
NINDS will support applications that address or seek fundamental knowledge about the brain and nervous system by supporting and conducting research on the healthy and diseased brain, spinal cord, and peripheral nerves and to use that knowledge to reduce the burden of neurological disease. NINDS supports basic, translational, and clinical research. NINDS also encourages activities focused on understanding and addressing disparities in neurologic health, healthcare, and health outcomes in disparate populations, including racial and ethnic minorities, the geographically disadvantaged, sex and gender minorities, and others who have been historically underserved, marginalized, and adversely affected by persistent inequality and socioeconomic disadvantage.
Only applications that fall within the scientific mission of the NINDS will be considered for funding (https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Mission) and the NINDS Strategic Plan (https://www.ninds.nih.gov/About-NINDS/Strategic-Plans-Evaluations/Strategic-Plans/NINDS-Strategic-Plan-and-Priorities/Neuroscience-Research).
NINR
The National Institute of Nursing Research (NINR) supports research to solve pressing health challenges and inform practice and policy - optimizing health and advancing health equity into the future. NINR discovers solutions to health challenges through the lenses of health equity, social determinants of health, population and community health, prevention and health promotion, and systems and models of care. Only applications that fall within these areas as detailed in the NINR 2022–2026 Strategic Plan will be considered. Drawing on the strengths of nursing’s holistic, contextualized perspective, core values, and broad reach, NINR funds multilevel and cross-sectoral research that examines the factors that impact health across the many settings in which nurses work, including homes, schools, workplaces, clinics, justice settings, and the community. Observational, intervention, and implementation research are of interest.
NIAAA
NIAAA will support applications that seek fundamental knowledge about the effecrts of alcohol on health and well being, and will apply that knowledge to improve diagnosis, prevention and treatment of alcohol related problems including alcohol use disorder, across the lifespan. NIAAA supports basic, translational and clinical research. Topics of interest include but are not limited to genetics, neuroscience, epidemiology, prevention and treatment of alcohol use disorder and alcohol related health conditions. NIAAAA also encourages activities focused on understanding and addressing disparities in the impact of alcohol use on health, heatlhcare accessand health outcomes in disparate popupulations. This includes racial and ethinc minorties, the geographically disadvantaged, sex and gender minorities and others who have been historically underserved, marginalized and adversely affected by prepsistent inequality and socioeconomic disadvantage.
NCCIH
NCCIH supports research regarding the use of complementary and integrative health approaches including natural products, mind and body interventions, and multicomponent interventions focused on whole person health. NCCIH is also interested in research studying mind and body approaches to manage stress, mild anxiety, or depression, or pain, and to improve adherence to treatment and prevention regimens to promote health outcomes. Natural products include botanicals, pre/probiotics, and products marketed as dietary supplements. Mind and body approaches include various meditation approaches (e.g., mindfulness), hypnosis or guided imagery, meditative movement approaches (e.g., yoga, tai chi, qi-gong), body-based approaches (e.g., spinal manipulation, massage, mobilization, acupuncture), a combination of these approaches (e.g., meditation and yoga, such as in mindfulness-based stress reduction MBSR), or complex interventions including music and art therapy. Research on whole person health includes multicomponent interventions designed to improve health in multiple interconnected domains: biological (including multiple organs and systems), behavioral, social, and environmental. NCCIH will not accept single-site or multi-site efficacy or effectiveness research through this FOA (please see NCCIH Clinical Trial Funding Opportunities instead). Applicants are strongly encouraged to discuss their plans with NCCIH Scientific/Research contact and to consult the NCCIH Strategic Plan to ensure their application addresses NCCIH scientific priorities prior to developing and submitting an application.
For applications proposing a clinical trial, note the following definitions and restrictions for this funding announcement:
- Clinical trials are research studies in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. For this funding announcement, only the following types of clinical trials will be supported:
- Mechanistic trials, defined as studies designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention (i.e., HOW an intervention works, but not IF it works or is safe).
- Basic Experimental Studies with Humans (BESH), defined as basic research studies involving humans that seek to understand the fundamental aspects of phenomena.
- Clinical trials that seek to answer specific questions about safety, tolerability, clinical efficacy, effectiveness, clinical management, and/or implementation of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions, preventive, therapeutic, and services interventions will not be supported under this FOA. Please refer to https://www.ninds.nih.gov/Funding/Find-Funding-Opportunities to find the appropriate NIH or NINDS-specific FOA for such clinical trials. In many cases, small interventional trials exploring an intervention are within scope of PAR-21-236: NINDS Exploratory Clinical Trials (U01 Clinical Trial Required). However, applicants are strongly encouraged to speak with the assigned Scientific/Research Contact prior to application.
- For further clarification on how NIH defines the different types of clinical trials, please refer to the following resources:
Applicants are strongly advised to consult with the appropriate IC Scientific/Research staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.
Per NOT-OD-16-011, the NIH expects applicants to apply rigor in designing and performing scientific research according to the NIH Principles and Guidelines for Reporting Preclinical Research.
NEI
The mission of the National Eye Institute (NEI) is to eliminate vision loss and improve quality of life through vision research. The NEI has framed its current strategic plan around this mission which addresses multiple opportunities as challenges in the vision field.
NEI will support applications that address or seek fundamental knowledge related to vision sciences, including, but not limited to: cellular and molecular neuroscience, imaging, genetics, development, basic/translational research on vision including how the visual system works from the eyes to the brain in health and disease. The overarching goal is to reduce visual impairment and blindness and thus resulting in an improvement in the quality of life for people of all ages. In all these areas and related areas of vision sciences research, NEI encourages an emphasis on understanding and addressing health disparities that are experienced by vulnerable populations.
For this funding opportunity, only the following trials will be supported by NEI.
- Mechanistic trials defined as studies designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention (i.e., HOW an intervention works, but not IF it works or is safe).
- Basic Experimental Studies with Humans (BESH) defined as basic research studies involving humans that seek to understand the fundamental aspects of phenomena.
Clinical trials that seek to answer specific questions about safety, tolerability, clinical efficacy, effectiveness, clinical management, and/or implementation of pharmacologic, biologic, surgical, or device (invasive or non-invasive) interventions, preventive, therapeutic, and services interventions will not be supported under this FOA. Please refer to https://www.nei.nih.gov/grants-and-training/funding-opportunities to find the appropriate NIH or NEI-specific FOA for such clinical trials.
Applications considered for funding by the NEI must fall within the areas of emphasis detailed in the NEI Strategic Plan. (NEI Strategic Plan: Vision for the Future (PDF 22.5 MB)
Modified to Read (changes shown in bold italics):
NIDA
NIDA will support applications that address or seek fundamental knowledge related to addiction sciences, including, but not limited to: cellular and molecular neuroscience, neuroimaging, genetics, medication and treatment development, development of new and improved strategies to prevent substance use and its consequences, neuroimmune signaling, neuropathology in brain systems, cognitive processes, population neuroscience, HIV and drugs of abuse (including basic discovery science research as well as applied research on delivery of HIV and substance use prevention and treatment services to persons who use drugs), medication development, epidemiology, identifying the biological, environmental, behavioral, and social causes and consequences of substance use and addiction across the lifespan, and implementation science, including secondary data analysis. In all these and related areas of addiction sciences research, NIDA encourages an emphasis on understanding and addressing health disparities which are experienced by vulnerable populations. Only applications that fall within the scientific mission of NIDA will be considered for funding (https://nida.nih.gov/about-nida/strategic-plan/directors-message).
NIMH
The mission of the National Institute of Mental Health (NIMH) is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery, and cure. NIMH supports research on topics that include basic neuroscience and behavioral science, and translational application of brain and behavior relationships in healthy and diseased states. Mental disorders may be defined according to existing diagnostic criteria or along dimensions of neurobehavioral functioning according to the NIMH Research Domain Criteria (RDoC) framework. If existing diagnostic criteria are to be used, investigators should include plans for addressing heterogeneity within the diagnostic category or categories. Applications considered for funding by the NIMH must fall within the areas of priority detailed in the NIMH Strategic Plan and the NIMH Strategic Research Priorities. It is recommended that investigators contact NIMH Scientific/Research staff well in advance of submitting applications to discuss the match to NIMH priorities. NIMH supports mechanistic clinical trials that focus on biomarker studies that may provide information about physiological function, target engagement of therapeutics, and/or the impact of therapeutic responses. These types of studies do not have as a primary aim to establish the efficacy or effectiveness of the intervention.
NIMH considers two major categories of mechanistic trials (though there may be others):
- Mechanistic clinical trials using an intervention of known efficacy. These clinical trials utilize an efficacious intervention to investigate the pathophysiology, and/or psychopathology of mental disorders or the mechanisms of therapeutic responses; and to advance biomarkers of basic neurobiological processes. In such studies: (1) the primary aims do not involve establishing efficacy/effectiveness, and (2) the intervention chosen has already been demonstrated to have efficacy.
- Mechanistic clinical trials utilizing an experimental manipulation: These studies utilize experimental manipulation and are primarily focused on understanding brain function in healthy individuals or those with mental disorders by measuring responses to the experimental manipulation. They are not intended to inform on the improvement of the health status of the individual or a group of individuals either by better understanding the mechanism of action of an intervention or a measurable improvement in health.
See the “Consolidated Notice on NIMH Clinical Trials Policies,”NOT-MH-20-105, for a summary of NIMH’s polices on support for mechanistic clinical trials.
NINDS
NINDS will support applications that address or seek fundamental knowledge about the brain and nervous system by supporting and conducting research on the healthy and diseased brain, spinal cord, and peripheral nerves and to use that knowledge to reduce the burden of neurological disease. NINDS supports basic, translational, and clinical research. NINDS also encourages activities focused on understanding and addressing disparities in neurologic health, healthcare, and health outcomes in disparate populations, including racial and ethnic minorities, the geographically disadvantaged, sex and gender minorities, and others who have been historically underserved, marginalized, and adversely affected by persistent inequality and socioeconomic disadvantage.
Only applications that fall within the scientific mission of the NINDS will be considered for funding (https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Mission) and the NINDS Strategic Plan (https://www.ninds.nih.gov/About-NINDS/Strategic-Plans-Evaluations/Strategic-Plans/NINDS-Strategic-Plan-and-Priorities/Neuroscience-Research).
NINR
The National Institute of Nursing Research (NINR) supports research to solve pressing health challenges and inform practice and policy - optimizing health and advancing health equity into the future. NINR discovers solutions to health challenges through the lenses of health equity, social determinants of health, population and community health, prevention and health promotion, and systems and models of care. Only applications that fall within these areas as detailed in the NINR 2022–2026 Strategic Plan will be considered. Drawing on the strengths of nursing’s holistic, contextualized perspective, core values, and broad reach, NINR funds multilevel and cross-sectoral research that examines the factors that impact health across the many settings in which nurses work, including homes, schools, workplaces, clinics, justice settings, and the community. Observational, intervention, and implementation research are of interest.
NIAAA
NIAAA will support applications that seek fundamental knowledge about the effects of alcohol on health and well being, and will apply that knowledge to improve diagnosis, prevention and treatment of alcohol related problems including alcohol use disorder, across the lifespan. NIAAA supports basic, translational and clinical research. Topics of interest include but are not limited to genetics, neuroscience, epidemiology, prevention and treatment of alcohol use disorder and alcohol related health conditions. NIAAA also encourages activities focused on understanding and addressing disparities in the impact of alcohol use on health, heatlhcare accessand health outcomes in disparate popupulations. This includes racial and ethinc minorties, the geographically disadvantaged, sex and gender minorities and others who have been historically underserved, marginalized and adversely affected by prepsistent inequality and socioeconomic disadvantage.
NCCIH
NCCIH supports research regarding the use of complementary and integrative health approaches including natural products, mind and body interventions, and multicomponent interventions focused on whole person health. NCCIH is also interested in research studying mind and body approaches to manage stress, mild anxiety, or depression, or pain, and to improve adherence to treatment and prevention regimens to promote health outcomes. Natural products include botanicals, pre/probiotics, and products marketed as dietary supplements. Mind and body approaches include various meditation approaches (e.g., mindfulness), hypnosis or guided imagery, meditative movement approaches (e.g., yoga, tai chi, qi-gong), body-based approaches (e.g., spinal manipulation, massage, mobilization, acupuncture), a combination of these approaches (e.g., meditation and yoga, such as in mindfulness-based stress reduction MBSR), or complex interventions including music and art therapy. Research on whole person health includes multicomponent interventions designed to improve health in multiple interconnected domains: biological (including multiple organs and systems), behavioral, social, and environmental. NCCIH will not accept single-site or multi-site efficacy or effectiveness research through this FOA (please see NCCIH Clinical Trial Funding Opportunities instead). Applicants are strongly encouraged to discuss their plans with NCCIH Scientific/Research contact and to consult the NCCIH Strategic Plan to ensure their application addresses NCCIH scientific priorities prior to developing and submitting an application.
For applications proposing a clinical trial, note the following definitions and restrictions for this funding announcement:
- Clinical trials are research studies in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. For this funding announcement, only the following types of clinical trials will be supported:
- Mechanistic trials, defined as studies designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention (i.e., HOW an intervention works, but not IF it works or is safe).
- Basic Experimental Studies with Humans (BESH), defined as basic research studies involving humans that seek to understand the fundamental aspects of phenomena.
- Clinical trials that seek to answer specific questions about safety, tolerability, clinical efficacy, effectiveness, clinical management, and/or implementation of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions, preventive, therapeutic, and services interventions will not be supported under this FOA. Please refer to https://www.ninds.nih.gov/Funding/Find-Funding-Opportunities to find the appropriate NIH or NINDS-specific FOA for such clinical trials. In many cases, small interventional trials exploring an intervention are within scope of PAR-21-236: NINDS Exploratory Clinical Trials (U01 Clinical Trial Required). However, applicants are strongly encouraged to speak with the assigned Scientific/Research Contact prior to application.
- For further clarification on how NIH defines the different types of clinical trials, please refer to the following resources:
Applicants are strongly advised to consult with the appropriate IC Scientific/Research staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.
Per NOT-OD-16-011, the NIH expects applicants to apply rigor in designing and performing scientific research according to the NIH Principles and Guidelines for Reporting Preclinical Research.
NEI
The mission of the National Eye Institute (NEI) is to eliminate vision loss and improve quality of life through vision research. The NEI has framed its current strategic plan around this mission which addresses multiple opportunities as challenges in the vision field.
NEI will support applications that address or seek fundamental knowledge related to vision sciences, including, but not limited to: cellular and molecular neuroscience, imaging, genetics, development, basic/translational research on vision including how the visual system works from the eyes to the brain in health and disease. The overarching goal is to reduce visual impairment and blindness and thus resulting in an improvement in the quality of life for people of all ages. In all these areas and related areas of vision sciences research, NEI encourages an emphasis on understanding and addressing health disparities that are experienced by vulnerable populations.
For this funding opportunity, only the following trials will be supported by NEI.
- Mechanistic trials defined as studies designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention (i.e., HOW an intervention works, but not IF it works or is safe).
- Basic Experimental Studies with Humans (BESH) defined as basic research studies involving humans that seek to understand the fundamental aspects of phenomena.
Clinical trials that seek to answer specific questions about safety, tolerability, clinical efficacy, effectiveness, clinical management, and/or implementation of pharmacologic, biologic, surgical, or device (invasive or non-invasive) interventions, preventive, therapeutic, and services interventions will not be supported under this FOA. Please refer to https://www.nei.nih.gov/grants-and-training/funding-opportunities to find the appropriate NIH or NEI-specific FOA for such clinical trials.
Applications considered for funding by the NEI must fall within the areas of emphasis detailed in the NEI Strategic Plan. (NEI Strategic Plan: Vision for the Future (PDF 22.5 MB)
NHGRI:
Relevance
There are many benefits to fostering a diverse workforce, for example promoting diversity of scientific ideas, understanding different perspectives from researchers, and maintaining cultures of inclusive excellence in the genomic research community. Enhancing the diversity of individuals participating as investigators in genomics research, may also help address the urgent need for enhanced diversity among those applying genomics in clinical care. The 2020 NHGRI Strategic Vision (PMID: 33116284 (https://pubmed.ncbi.nlm.nih.gov/33116284/)) lists “Champion a diverse workforce” as one of the guiding principles/values for human genomics. To pursue this, the NHGRI recently published its action agenda for building a diverse genomics workforce (Bonham, Green, 2021 (https://www.cell.com/ajhg/fulltext/S0002-9297(20)30449-3) AJHG), the result of an intensive year-long task force effort to develop a workforce diversity strategic plan and produce initiatives needed to enhance diversity, including addressing groups nationally underrepresented in the genomics research workforce. This initiative is part of that emerging portfolio of initiatives and is intended to address the third strategic goal of that action agenda, to develop and support research transition programs to independent genomic research careers.
Applicants to NHGRI may propose any research topic suitable for an R01 within the NHGRI mission as described on the NHGRI website for the Division of Genome Sciences, the Division of Genomic Medicine, and the Ethical, Legal and Social Implications Research Program.
Consent Expectations
Where human biological samples will be studied, they are expected to have been obtained using a documented informed consent process that allows for future research use and broad data sharing (NOT-HG-20-011). If new human biospecimens will be collected, or if clinical application is included in the application, the consent process should be described at a high level in the Research Plan and detailed in the Human Subjects Section.
NHGRI strongly encourages studies that propose to derive genomic data from human specimens and cell lines to obtain participant consent either for general research use through controlled access or for unrestricted access. Similarly, consent language should avoid both restrictions on the types of users who may access the data and restrictions that add additional requirements to the access request process. NHGRI acknowledges that this will not always be possible or appropriate. In addition, individual participants who do not consent to future research use or broad sharing of their data (i.e., submission of their data to a publicly accessible data repository) may still participate in the primary study if consistent with study design. Additional guidance on informed consent can be found in the NHGRI Informed Consent Resource.
NHGRI expects non-human genomic data that are subject to the NIH GDS Policy to be submitted and released on the same timeline as human genomic data.
Metadata and Phenotypic Data
Per NOT-HG-21-022 (https://grants.nih.gov/grants/guide/notice-files/NOT-HG-21-022.html), NHGRI expects applications awarded under this NOFO to share comprehensive metadata and phenotypic data associated with the study, use standardized data collection protocols and survey instruments for capturing data, as appropriate, and use standardized notation for metadata (e.g., controlled vocabularies or ontologies) to enable the harmonization of datasets for secondary research analyses.
Section II. Award Information
Funds Available and Anticipated Number of Awards
Currently Reads:
The following NIH components intend to commit the following amounts for the duration of this PAR:
NINDS intends to commit up to $10 million per fiscal year, approximately 25 awards, dependent on award amounts
NIDA intends to commit up to $5 million per fiscal year, 12-15 awards, dependent on award amounts
NIMH intends to commit up to $5 million per fiscal year, 12-15 awards, dependent on award amounts
NINR intends to commit up to $1 million per fiscal year, 2-3 awards, dependent on award amounts
NIAAA intends to commit up to $1.5 million per fiscal year, 2-3 awards, dependent on award amounts
NCCIH intends to commit up to $400,000 per fiscal year, 1 award, dependent on award amounts
Future year amounts will depend on annual appropriations.
Modified to Read (changes shown in bold italics):
The following NIH components intend to commit the following amounts for the duration of this PAR:
NINDS intends to commit up to $10 million per fiscal year, approximately 25 awards, dependent on award amounts
NIDA intends to commit up to $5 million per fiscal year, 12-15 awards, dependent on award amounts
NIMH intends to commit up to $5 million per fiscal year, 12-15 awards, dependent on award amounts
NINR intends to commit up to $1 million per fiscal year, 2-3 awards, dependent on award amounts
NIAAA intends to commit up to $1.5 million per fiscal year, 2-3 awards, dependent on award amounts
NCCIH intends to commit up to $400,000 per fiscal year, 1 award, dependent on award amounts
NHGRI’s number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Future year amounts will depend on annual appropriations.
Section VII. Agency Contacts
Scientific/Research Contact(s)
Currently Reads:
Will M. Aklin, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-5909
Email: aklinwm@mail.nih.gov
Michelle Jones-London, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-451-7966
Email: NINDSDiversityTraining@mail.nih.gov
Lauren D. Hill, PhD
National Institute of Mental Health (NIMH)
Telephone: 301-443-2638
Email: hillla@mail.nih.gov
Shalanda A. Bynum, PhD, MPH
National Institute of Nursing Research (NINR)
Telephone: 301-755-4355
Email: shalanda.bynum@nih.gov
Laura Kwako, Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-451-8507
Email: laura.kwako@nih.gov
Beda Jean-Francois
National Center for Complementary & Integrative Health (NCCIH)
Telephone: 202-313-2144
Email: beda.jean-francois@nih.gov
Neeraj Agarwal, PhD
National Eye Institute (NEI)
Telephone: 301-435-8155
Email:agarwalnee@nei.nih.gov
Modified to Read (changes shown in bold italics):
Will M. Aklin, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-5909
Email: aklinwm@mail.nih.gov
Michelle Jones-London, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-451-7966
Email: NINDSDiversityTraining@mail.nih.gov
Lauren D. Hill, PhD
National Institute of Mental Health (NIMH)
Telephone: 301-443-2638
Email: hillla@mail.nih.gov
Shalanda A. Bynum, PhD, MPH
National Institute of Nursing Research (NINR)
Telephone: 301-755-4355
Email: shalanda.bynum@nih.gov
Laura Kwako, Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-451-8507
Email: laura.kwako@nih.gov
Beda Jean-Francois
National Center for Complementary & Integrative Health (NCCIH)
Telephone: 202-313-2144
Email: beda.jean-francois@nih.gov
Neeraj Agarwal, PhD
National Eye Institute (NEI)
Telephone: 301-435-8155
Email:agarwalnee@nei.nih.gov
Jyoti Dayal, M.S.
National Human Genome Research Institute (NHGRI)
Telephone: 301-480-2307
Email: jyotig@mail.nih.gov
Financial/Grants Management Contact(s)
Currently Reads:
Pamela Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-253-8927
Email: pfleming@nida.nih.gov
Chief Grants Management Officer
National Institute of Neurological Disorders and Stroke (NINDS)
Email: ChiefGrantsManagementOfficer@ninds.nih.gov
Terri Jarosik
National Institute of Mental Health (NIMH)
Telephone: 301-443-3858
Email: tjarosik@mail.nih.gov
Kelli Oster
National Institute of Nursing Research (NINR)
Telephone: 301-594-2177
Email: osterk@mail.nih.gov
Judy Fox
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-443-4707
Email: jfox@mail.nih.gov
Debbie Chen
National Center for Complementary and Integrative Health (NCCIH)
Telephone: 301-594-3788
Email: debbie.chen@nih.gov
Karen Robinson-Smith
National Eye Institute (NEI)
Telephone: 301-435-8178
Email: karen.robinson.smith@nei.nih.gov
Modified to Read (changes shown in bold italics):
Pamela Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-253-8927
Email: pfleming@nida.nih.gov
Chief Grants Management Officer
National Institute of Neurological Disorders and Stroke (NINDS)
Email: ChiefGrantsManagementOfficer@ninds.nih.gov
Terri Jarosik
National Institute of Mental Health (NIMH)
Telephone: 301-443-3858
Email: tjarosik@mail.nih.gov
Kelli Oster
National Institute of Nursing Research (NINR)
Telephone: 301-594-2177
Email: osterk@mail.nih.gov
Judy Fox
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-443-4707
Email: jfox@mail.nih.gov
Debbie Chen
National Center for Complementary and Integrative Health (NCCIH)
Telephone: 301-594-3788
Email: debbie.chen@nih.gov
Karen Robinson-Smith
National Eye Institute (NEI)
Telephone: 301-435-8178
Email: karen.robinson.smith@nei.nih.gov
Natalie Linear
National Human Genome Research Institute (NHGRI)
Telephone: 301-827-0611
Email: natalie.linear@mail.nih.gov
Jyoti Dayal, M.S.
National Human Genome Research Institute (NHGRI)
Telephone: 301-480-2307
Email: jyotig@mail.nih.gov
and Human Services (HHS)
